BioSpace News Archive

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the closing of its previously announced underwritten public offering of 13,333,334 common shares (the “Offering”). The shares were sold at a public offering price of US$15.00 per share. The gross offering pro

Critical first line of defense against COVID-19 using thermal scanning

Two groups of nerve cells may serve as “on-off switches” for male mating and aggression, suggests a new study in rodents.

ProMab Biotechnology, Inc., a leading developer of CAR-T/NK cell technology for global life sciences, announced today it has successfully completed an investigator initiated trail (IIT) for CAR-T cell therapy. The study was conducted at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology by Prof. Hu Yu and Prof. Mei Heng in collaboration with Wuhan Sian Medical Technology using ProMab’s

ams, a leading worldwide supplier of high performance sensor solutions, has been thanked by long-term customer, United Imaging Healthcare Co., Ltd for its outstanding contribution to helping hospitals in China to diagnose respiratory complications of some of the first Covid-19 patients.

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), today announced it has entered into a letter of intent with Healthimation, LLC (“Healthimation”) relating to a possible acquisition of the Healthi

Trinity Life Sciences, a leader in global life sciences solutions, published a new forecasting paper entitled Considerations for Forecasting the Spread of COVID-19: How can life sciences companies most accurately project the spread of COVID-19 to plan for the future?

Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s Disease and related disorders that arise inside and outside of the brain, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the pro

Mindera Corporation has announced that George W. Mahaffey was appointed President and Chief Executive Officer, and will also serve as a Director of the Company. Treatment of chronic skin conditions is a

Vave Health, a maker of innovative handheld ultrasound technology, today announced Dr. Renee Dversdal as its chief medical officer.